ST. PAUL, Minn., June 7 /PRNewswire/ -- UltiMed, Inc. today announced that it has filed a lawsuit in the United States District Court for the District of Minnesota against Becton, Dickinson and Company (“BD”) seeking damages and injunctive relief related to alleged antitrust violations and torts committed by BD. UltiMed’s complaint alleges that BD has engaged in anticompetitive acts to maintain monopoly power in the home use insulin syringe market. The complaint further alleges that “BD’s anticompetitive acts have harmed the public by causing higher prices for home use insulin syringes, stifling product research and development, and driving health insurance costs higher [and] have harmed UltiMed by preventing UltiMed from competing on a level economic playing field despite UltiMed’s efforts to sell equal or superior quality products at more economical prices.”
